KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Boston Scientific (BSX) over the last 17 years, with Q4 2025 value amounting to $220.0 million.

  • Boston Scientific's Non-Current Deferred Tax Liability fell 90.09% to $220.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $220.0 million, marking a year-over-year decrease of 90.09%. This contributed to the annual value of $220.0 million for FY2025, which is 90.09% down from last year.
  • Per Boston Scientific's latest filing, its Non-Current Deferred Tax Liability stood at $220.0 million for Q4 2025, which was down 90.09% from $242.0 million recorded in Q3 2025.
  • In the past 5 years, Boston Scientific's Non-Current Deferred Tax Liability registered a high of $336.0 million during Q1 2021, and its lowest value of $91.0 million during Q3 2023.
  • Over the past 5 years, Boston Scientific's median Non-Current Deferred Tax Liability value was $215.0 million (recorded in 2023), while the average stood at $201.5 million.
  • As far as peak fluctuations go, Boston Scientific's Non-Current Deferred Tax Liability crashed by 8034.19% in 2021, and later skyrocketed by 13043.48% in 2022.
  • Quarter analysis of 5 years shows Boston Scientific's Non-Current Deferred Tax Liability stood at $310.0 million in 2021, then crashed by 51.29% to $151.0 million in 2022, then fell by 11.26% to $134.0 million in 2023, then surged by 65.67% to $222.0 million in 2024, then fell by 0.9% to $220.0 million in 2025.
  • Its last three reported values are $220.0 million in Q4 2025, $242.0 million for Q3 2025, and $226.0 million during Q2 2025.